HRP20231076T1 - Postupci detektiranja neutralizirajućih protutijela protiv leptina - Google Patents
Postupci detektiranja neutralizirajućih protutijela protiv leptina Download PDFInfo
- Publication number
- HRP20231076T1 HRP20231076T1 HRP20231076TT HRP20231076T HRP20231076T1 HR P20231076 T1 HRP20231076 T1 HR P20231076T1 HR P20231076T T HRP20231076T T HR P20231076TT HR P20231076 T HRP20231076 T HR P20231076T HR P20231076 T1 HRP20231076 T1 HR P20231076T1
- Authority
- HR
- Croatia
- Prior art keywords
- leptin
- labeled
- signal
- sample
- coated matrix
- Prior art date
Links
- 229940039781 leptin Drugs 0.000 title claims 33
- 238000000034 method Methods 0.000 title claims 13
- 230000003472 neutralizing effect Effects 0.000 title claims 7
- 102000016267 Leptin Human genes 0.000 claims 29
- 108010092277 Leptin Proteins 0.000 claims 29
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 29
- 239000011159 matrix material Substances 0.000 claims 11
- 239000000758 substrate Substances 0.000 claims 11
- 102000005861 leptin receptors Human genes 0.000 claims 6
- 108010019813 leptin receptors Proteins 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 5
- 239000008280 blood Substances 0.000 claims 5
- 210000002381 plasma Anatomy 0.000 claims 5
- 210000002966 serum Anatomy 0.000 claims 5
- 230000000415 inactivating effect Effects 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 3
- 238000005406 washing Methods 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 claims 2
- 239000013642 negative control Substances 0.000 claims 2
- 239000013641 positive control Substances 0.000 claims 2
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 claims 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 108700008455 metreleptin Proteins 0.000 claims 1
- 229960000668 metreleptin Drugs 0.000 claims 1
- 229910052707 ruthenium Inorganic materials 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (12)
1. Postupak detektiranja neutralizirajućih protutijela protiv leptina u uzorku, naznačen time što se sastoji u koracima:
(a) inaktiviranja leptina prisutnog u uzorku;
(b) dodavanja poznate količine obilježenog leptina u uzorak;
(c) stavljanja u kontakt uzorka koji sadrži obilježeni leptin iz (b) sa supstratom koji se može vezati na obilježeni leptin, gdje navedeni supstrat koji se može vezati na obilježeni leptin sadrži obloženu matricu i obilježeni leptinski receptor vezan na obloženu matricu;
(d) ispiranja supstrata kako bi se uklonilo nevezani obilježeni leptin; i
(e) mjerenja signala iz biljega kojeg proizvodi obilježeni leptin vezan na supstrat.
2. Postupak identificiranja subjekata koji imaju neutralizirajuća protutijela protiv leptina u krvi, serumu ili plazmi iz subjekta, naznačen time što se sastoji u koracima:
(a) inaktiviranja leptina i leptina prisutnog u uzorku subjektove krvi, seruma ili plazme;
(b) dodavanja poznate količine obilježenog leptina u uzorak;
(c) stavljanja u kontakt uzorka koji sadrži obilježeni leptin iz (b) sa supstratom koji se može vezati na obilježeni leptin, gdje navedeni supstrat koji se može vezati na obilježeni leptin sadrži obloženu matricu i obilježeni leptinski receptor vezan na obloženu matricu;
(d) ispiranja supstrata kako bi se uklonilo nevezani obilježeni leptin;
(e) mjerenja signala iz biljega kojeg proizvodi vezani obilježeni leptin;
(f) mjerenja pozitivnog kontrolnog signala, gdje se navedeni pozitivni kontrolni signal proizvodi provođenjem koraka (a)-(e), te dodatno uključuje dodavanje poznate količine protutijela protiv leptina u koraku (b); i
(g) uspoređivanja signala iz (e) sa signalom iz (f), gdje ako je razina signala izmjerenog u koraku (e) jednaka ili niža od razine signala izmjerenog u koraku (f), subjekt daje pozitivan test na neutralizirajuća protutijela protiv leptina.
3. Postupak identificiranja subjekata koji imaju neutralizirajuća protutijela protiv leptina u krvi, serumu ili plazmi iz subjekta, naznačen time što se sastoji u koracima:
(a) inaktiviranja leptina prisutnog u uzorku krvi, seruma ili plazme;
(b) dodavanja poznate količine obilježenog leptina u uzorak;
(c) stavljanja u kontakt uzorka koji sadrži obilježeni leptin iz (b) sa supstratom koji se može vezati na obilježeni leptin, gdje navedeni supstrat koji se može vezati na obilježeni leptin sadrži obloženu matricu i obilježeni leptinski receptor vezan na obloženu matricu;
(d) ispiranja supstrata kako bi se uklonilo nevezani obilježeni leptin;
(e) mjerenja signala iz biljega kojeg proizvodi vezani obilježeni leptin;
(f) mjerenja negativnog kontrolnog signala, gdje se navedeni negativni kontrolni signal proizvodi provođenjem koraka (a)-(e), gdje uzorak krvi, seruma ili plazme ne sadrži neutralizirajuća protutijela protiv leptina; i
(g) uspoređivanja postotne razlike u signalu iz (e) i signalu iz (f) s rubnom točkom, gdje ako je postotna razlika u signalu iz (e) i signalu iz (f) veća od rubne točke, subjekt daje pozitivan test na neutralizirajuća protutijela protiv leptina.
4. Postupak u skladu s patentnim zahtjevom 3, naznačen time što je rubna točka između otprilike 5% i otprilike 40%.
5. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je leptin obilježen peroksidazom iz hrena ili tris(bipiridin)rutenijem.
6. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se korak inaktiviranja (a) provodi grijanjem uzorka.
7. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što je obložena matrica matrica obložena streptavidinom.
8. Postupak u skladu s patentnim zahtjevom 7, naznačen time što je leptinski receptor obilježen biotinom.
9. Postupak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što navedeni supstrat koji se može vezati na obilježeni leptin sadrži:
(i) obloženu matricu;
(ii) protutijelo vezano na matricu iz (i); i
(iii) obilježeni leptinski receptor, vezan na protutijelo iz (ii).
10. Postupak u skladu s patentnim zahtjevom 9, naznačen time što je leptinski receptor obilježen heksahistidinskim biljegom, a protutijelo je protutijelo protiv heksahistidina.
11. Postupak u skladu s bilo kojim od patentnih zahtjeva 9 i 10, naznačen time što je protutijelo obilježeno biljegom pogodnim za vezanje na obloženu matricu.
12. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je obilježeni leptin dodan u koraku (b) obilježeni metreleptin.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662393632P | 2016-09-12 | 2016-09-12 | |
| PCT/US2017/051232 WO2018049424A1 (en) | 2016-09-12 | 2017-09-12 | Methods of detecting anti-leptin neutralizing antibodies |
| EP17849795.4A EP3509624B1 (en) | 2016-09-12 | 2017-09-12 | Methods of detecting anti-leptin neutralizing antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231076T1 true HRP20231076T1 (hr) | 2023-12-22 |
Family
ID=61559769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231076TT HRP20231076T1 (hr) | 2016-09-12 | 2017-09-12 | Postupci detektiranja neutralizirajućih protutijela protiv leptina |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10775386B2 (hr) |
| EP (2) | EP4283304A3 (hr) |
| JP (1) | JP7139317B2 (hr) |
| CN (1) | CN110139663B (hr) |
| BR (1) | BR112019004715A2 (hr) |
| CA (1) | CA3036551A1 (hr) |
| DK (1) | DK3509624T3 (hr) |
| EA (1) | EA201990720A1 (hr) |
| ES (1) | ES2959990T3 (hr) |
| FI (1) | FI3509624T3 (hr) |
| HR (1) | HRP20231076T1 (hr) |
| HU (1) | HUE063647T2 (hr) |
| MX (1) | MX2019002818A (hr) |
| PL (1) | PL3509624T3 (hr) |
| PT (1) | PT3509624T (hr) |
| RS (1) | RS64850B1 (hr) |
| SI (1) | SI3509624T1 (hr) |
| WO (1) | WO2018049424A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3036551A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
| CA3104120A1 (en) * | 2018-06-16 | 2019-12-19 | Board Of Regents, The University Of Texas System | Weight loss regimen |
| WO2020028764A1 (en) * | 2018-08-03 | 2020-02-06 | Bristol-Myers Squibb Company | Methods for detecting anti-drug antibodies |
| CN111983226A (zh) * | 2020-03-25 | 2020-11-24 | 新加坡国立大学 | SARSr-CoV抗体的检测 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| AU4766196A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Anti-obesity proteins |
| US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
| US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
| US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
| US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
| AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
| CN1195293A (zh) | 1995-06-30 | 1998-10-07 | 伊莱利利公司 | 治疗糖尿病的方法 |
| DK0865294T3 (da) | 1995-08-17 | 2004-06-28 | Amgen Inc | Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| CA2358862A1 (en) | 1995-11-22 | 1997-05-29 | Amgen Inc. | Methods of increasing lean tissue mass using ob protein compositions |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| WO1997038014A1 (en) | 1996-04-04 | 1997-10-16 | Amgen Inc. | Fibulin pharmaceutical compositions and related methods |
| AU4075897A (en) * | 1996-08-16 | 1998-03-06 | Roger Lallone | A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway |
| EP1001768A1 (en) | 1996-08-30 | 2000-05-24 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
| JP2001500869A (ja) | 1996-09-20 | 2001-01-23 | ヘキスト、アクチェンゲゼルシャフト | 第ｉｉ種糖尿病におけるインスリン耐性を治療するためのレプチンアンタゴニストの使用 |
| CA2275183A1 (en) | 1996-12-20 | 1998-07-02 | Amgen Inc. | Ob fusion protein compositions and methods |
| JP4086908B2 (ja) | 1997-04-17 | 2008-05-14 | アムジエン・インコーポレーテツド | 安定かつ活性なヒトＯＢタンパク質と抗体Ｆｃ鎖とのコンジュゲートを含む組成物および方法 |
| EP0986397A1 (en) | 1997-06-06 | 2000-03-22 | Smithkline Beecham Plc | Use of leptin antagonists for the treatment of diabet |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| ES2228082T3 (es) | 1998-08-10 | 2005-04-01 | Amgen Inc. | Conjugados dextrano-leptina, composiciones farmaceuticas y metodos relacionados. |
| EP1118001A1 (en) | 1998-10-02 | 2001-07-25 | Amgen Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| DE60027409T2 (de) | 1999-02-12 | 2007-04-12 | Amgen Inc., Thousand Oaks | Glykosylierte leptinzusammensetzungen und zugehörige verfahren |
| MXPA04003773A (es) | 2001-10-22 | 2004-07-30 | Amgen Inc | Uso de leptina para tratar lipoatrofia humana y metodo para determinar la predisposicion a dicho tratamiento. |
| WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
| WO2004078944A2 (en) * | 2003-03-05 | 2004-09-16 | Maine Medical Center Research Institute | Thrombin, soluble jaggedi, and trap and growth of stem cells |
| WO2005022156A1 (ja) | 2003-08-29 | 2005-03-10 | Reverse Proteomics Research Institute Co., Ltd. | タンパク質の固定化方法 |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| US7320868B2 (en) * | 2004-03-19 | 2008-01-22 | Arieh Gertler | Leptin binding domain compositions and methods thereto |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| WO2009064298A1 (en) | 2007-11-14 | 2009-05-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity and obesity related diseases and disorders |
| GB201004058D0 (en) * | 2010-03-11 | 2010-04-28 | Consiglio Nazionale Ricerche | Diagnostic assay for obesity and related disorders |
| MX349054B (es) | 2010-09-28 | 2017-07-07 | Aegerion Pharmaceuticals Inc | Leptinas altamente solubles. |
| US20130266963A1 (en) * | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
| PT2729160T (pt) | 2011-07-08 | 2019-07-08 | Aegerion Pharmaceuticals Inc | Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida |
| RU2701684C2 (ru) | 2013-10-31 | 2019-09-30 | Ридженерон Фармасьютикалз, Инк. | Анализ конкурентного связывания с лигандом для обнаружения нейтрализирующих антител |
| WO2016138355A1 (en) * | 2015-02-27 | 2016-09-01 | Ionis Pharmaceuticals, Inc. | Modulation of apolipoprotein c-iii (apociii) expression in lipodystrophy populations |
| CA3036551A1 (en) | 2016-09-12 | 2018-03-15 | Aegerion Pharmaceuticals, Inc. | Methods of detecting anti-leptin neutralizing antibodies |
-
2017
- 2017-09-12 CA CA3036551A patent/CA3036551A1/en active Pending
- 2017-09-12 JP JP2019513974A patent/JP7139317B2/ja active Active
- 2017-09-12 US US15/702,719 patent/US10775386B2/en active Active
- 2017-09-12 SI SI201731435T patent/SI3509624T1/sl unknown
- 2017-09-12 FI FIEP17849795.4T patent/FI3509624T3/fi active
- 2017-09-12 PT PT178497954T patent/PT3509624T/pt unknown
- 2017-09-12 HR HRP20231076TT patent/HRP20231076T1/hr unknown
- 2017-09-12 WO PCT/US2017/051232 patent/WO2018049424A1/en active Application Filing
- 2017-09-12 EA EA201990720A patent/EA201990720A1/ru unknown
- 2017-09-12 ES ES17849795T patent/ES2959990T3/es active Active
- 2017-09-12 RS RS20231049A patent/RS64850B1/sr unknown
- 2017-09-12 BR BR112019004715A patent/BR112019004715A2/pt unknown
- 2017-09-12 PL PL17849795.4T patent/PL3509624T3/pl unknown
- 2017-09-12 MX MX2019002818A patent/MX2019002818A/es unknown
- 2017-09-12 EP EP23188153.3A patent/EP4283304A3/en active Pending
- 2017-09-12 HU HUE17849795A patent/HUE063647T2/hu unknown
- 2017-09-12 DK DK17849795.4T patent/DK3509624T3/da active
- 2017-09-12 CN CN201780069880.XA patent/CN110139663B/zh active Active
- 2017-09-12 EP EP17849795.4A patent/EP3509624B1/en active Active
-
2020
- 2020-08-18 US US16/996,281 patent/US11709166B2/en active Active
-
2023
- 2023-06-07 US US18/330,550 patent/US20230314447A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS64850B1 (sr) | 2023-12-29 |
| EP3509624A1 (en) | 2019-07-17 |
| BR112019004715A2 (pt) | 2019-07-16 |
| HUE063647T2 (hu) | 2024-01-28 |
| PL3509624T3 (pl) | 2024-03-25 |
| EP4283304A3 (en) | 2024-02-28 |
| JP2019529904A (ja) | 2019-10-17 |
| EP3509624B1 (en) | 2023-08-09 |
| ES2959990T3 (es) | 2024-02-29 |
| EP4283304A2 (en) | 2023-11-29 |
| PT3509624T (pt) | 2023-08-28 |
| EA201990720A1 (ru) | 2019-08-30 |
| JP2022176209A (ja) | 2022-11-25 |
| FI3509624T3 (fi) | 2023-10-18 |
| WO2018049424A1 (en) | 2018-03-15 |
| CN110139663B (zh) | 2024-05-07 |
| US20200378988A1 (en) | 2020-12-03 |
| CN110139663A (zh) | 2019-08-16 |
| MX2019002818A (es) | 2019-08-29 |
| JP7139317B2 (ja) | 2022-09-20 |
| US10775386B2 (en) | 2020-09-15 |
| US20180074073A1 (en) | 2018-03-15 |
| US11709166B2 (en) | 2023-07-25 |
| DK3509624T3 (da) | 2023-11-13 |
| EP3509624A4 (en) | 2020-02-19 |
| SI3509624T1 (sl) | 2023-12-29 |
| CA3036551A1 (en) | 2018-03-15 |
| US20230314447A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231076T1 (hr) | Postupci detektiranja neutralizirajućih protutijela protiv leptina | |
| Zhang et al. | A polyaniline based ultrasensitive potentiometric immunosensor for cardiac troponin complex detection | |
| HRP20201856T1 (hr) | Antitijela koja se vežu za ljudski ligand i programiranje smrti (pd-l1) | |
| Choi et al. | Development of SPR biosensor for the detection of human hepatitis B virus using plasma-treated parylene-N film | |
| JP2019535015A5 (hr) | ||
| Jeon et al. | An electroactive biotin‐doped polypyrrole substrate that immobilizes and releases EpCAM‐positive cancer cells | |
| JP2019530875A5 (hr) | ||
| JP2009521215A5 (hr) | ||
| Riedel et al. | Diagnosis of Epstein–Barr virus infection in clinical serum samples by an SPR biosensor assay | |
| SI2524060T1 (en) | Investigation for JC virus antibodies | |
| JP2020537128A5 (hr) | ||
| WO2013132347A3 (en) | Improved elisa immunoassay for calprotectin | |
| HRP20171310T1 (hr) | Postupci procjenjivanja imunosnog odgovora na terapijsko sredstvo | |
| JP2014517311A5 (hr) | ||
| CN105393119A (zh) | 用于免疫试验的多重封闭物珠 | |
| JP2014055944A5 (hr) | ||
| JP2012073260A5 (hr) | ||
| SE0201468D0 (sv) | Metod att använda luminescenta polymerer för detektion av biospecifik växelverkan | |
| JP2012509477A5 (hr) | ||
| RU2014133701A (ru) | Способ детекции партнера по связыванию мультиспецифического связывающего агента | |
| JP2017026631A5 (hr) | ||
| JP6764852B2 (ja) | 蛋白質吸着抑制方法 | |
| Kokla et al. | Visualization of the membrane engineering concept: Evidence for the specific orientation of electroinserted antibodies and selective binding of target analytes | |
| RU2014125266A (ru) | Анализ содержания фибриногена | |
| Gao et al. | A rapid assay for Hendra virus IgG antibody detection and its titre estimation using magnetic nanoparticles and phycoerythrin |